Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.

James Frates Biography and Net Worth

Director of Sage Therapeutics

James Frates serves as Chief Financial Officer at Amylyx Pharmaceuticals. Prior to joining Amylyx, he was Alkermes Chief Financial Officer for almost 23 years through its growth from a clinical stage company to an international commercial and development enterprise with multiple products in CNS, over $1 billion in revenue and over 2,000 employees. Earlier in his career, Jim was a Vice President in charge of the East Coast Life Sciences Practice at Robertson Stephens & Company. He also worked in healthcare investment banking at Morgan Stanley & Company and spent a year teaching secondary school at the Royal Shrewsbury School in the U.K., as the Harvard College Fellow. Jim served on the Board of Directors of GPC Biotech AG from June 2004 to June 2009 and was a national director of the Association of Bioscience Financial Officers. He also serves as a Trustee for St. Francis House, Boston’s largest day shelter for the homeless. He has previously served as a trustee and Treasurer for the Roxbury Latin School and St Paul’s School. Jim received a Bachelor of Arts degree in government from Harvard College and a Master of Business Administration from Harvard Graduate School of Business Administration.

What is James M. Frates' net worth?: The estimated net worth of James M. Frates is at least $1.21 million as of September 12th, 2024. Mr. Frates owns 233,464 shares of Sage Therapeutics stock worth more than $1,207,009 as of November 23rd. This net worth estimate does not reflect any other investments that Mr. Frates may own. Learn More about James M. Frates' net worth.
How do I contact James M. Frates?: The corporate mailing address for Mr. Frates and other Sage Therapeutics executives is 215 FIRST STREET, CAMBRIDGE MA, 02142. Sage Therapeutics can also be reached via phone at (617) 299-8380 and via email at [email protected]. Learn More on James M. Frates' contact information.
Has James M. Frates been buying or selling shares of Sage Therapeutics?: James M. Frates has not been actively trading shares of Sage Therapeutics within the last three months. Most recently, on Wednesday, June 16th, James M. Frates bought 1,810 shares of Sage Therapeutics stock. The stock was acquired at an average cost of $55.10 per share, with a total value of $99,731.00. Following the completion of the transaction, the director now directly owns 1,035 shares of the company's stock, valued at $57,028.50. Learn More on James M. Frates' trading history.
Who are Sage Therapeutics' active insiders?: Sage Therapeutics' insider roster includes James Frates (Director), and Barry Greene (CEO). Learn More on Sage Therapeutics' active insiders.

James M. Frates Insider Trading History at Sage Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/16/2021	Buy	1,810	$55.10	$99,731.00	1,035
8/15/2019	Sell	8,000	$160.58	$1,284,640.00
5/6/2019	Sell	8,000	$162.22	$1,297,760.00	12,235
1/23/2019	Sell	7,500	$134.81	$1,011,075.00	11,735
5/8/2018	Sell	7,000	$154.00	$1,078,000.00	12,000
7/23/2014	Buy	5,000	$18.00	$90,000.00

James M. Frates Buying and Selling Activity at Sage Therapeutics

Sage Therapeutics Company Overview

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $5.17

$4.85

$5.21

50 Day Range

MA: $6.70

$4.78

$8.54

2 Week Range

Now: $5.17

$4.62

$28.26

Volume

871,036 shs

Average Volume

947,916 shs

Market Capitalization

$316.25 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.92

Trump won. Buy this coin now.

From Weiss Ratings | Ad